AstraZeneca’s Imfinzi demonstrates significant survival benefits in Phase 3 ADRIATIC trial

In a significant advancement for cancer treatment, AstraZeneca's Imfinzi (durvalumab) has emerged as the first and only immunotherapy to show a survival benefit in a ... Read More